CAM: What I find interesting is that highly addictive substances are easily accessible, while substances with restrictions are less addictive. As we wrap up, I want to ask two questions regarding the controversy surrounding psychedelics. You mentioned that there hasn't been a breakthrough in psychiatry and psychology for the past 50 years, and now you're introducing this revolutionary approach.
What are some of the controversies, and how are you navigating them?
Brad : Some of the current controversies stem from a lack of insight and knowledge about these medicines, even within the medical community. This lack of understanding leads to stigma, myths, and misconceptions about these medicines. One common myth is that psychedelics will induce psychosis or make people see Martians forever. However, any medicine used out of context, without proper protocols and a therapeutic framework, can be harmful. Another misconception is that these substances are not as powerful as people think because a few studies may suggest that the benefits are not long- lasting. But the question is, compared to what? Compared to antidepressants with a 33 to 48% efficacy rate? Ketamine is not a magic bullet, but it is a significant improvement over existing options. To correct these narratives, we are being responsible and thorough with our therapeutic frameworks. We aim to shift the focus from relying solely on medicine to emphasizing integration therapy, where insights gained from the medicine can be translated into behavioural changes. Psychedelic medicine is not a replacement but an additional tool in a vast therapeutic toolbox. It accelerates and catalyses the work individuals are already doing, complementing existing therapies and interventions developed by experts in the field over the past century.
Psychedelic- Assisted Therapy
58
June 2023 | Collective Action Magazine Collective Action Magazine
Made with FlippingBook - PDF hosting